Molecular Partners AG
0QXX.L
London Stock Exchange3.22
CHF
+0.04
- -
Molecular Partners AG
0QXX.L
(London Stock Exchange)
Recent
price
3.22
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotechnology company that pioneers the design and development of DARPin therapeutics, a proprietary class of custom-built protein drugs engineered to address unmet medical needs in oncology and other serious diseases. The company offers a diverse pipeline of investigational products, including MP0533, a tetra-specific T cell engager targeting CD33 x CD123 x CD70 x CD3 for relapsed/refractory acute myeloid leukemia (r/r AML) and AML/MDS in Phase 1 trials; MP0317, a FAP x CD40 tumor-localized agonist for advanced solid tumors in Phase 1; MP0712, a 212Pb x DLL3 Radio-DARPin therapy for small cell lung cancer (SCLC) and neuroendocrine tumors advancing toward first-in-human trials with an IND filing anticipated in 2025; MP0726, a 212Pb x MSLN Radio-DARPin therapy for ovarian cancer; MP0621, a cKIT x CD16a x CD47 Switch-DARPin for hematopoietic stem cell conditioning in preclinical development; and ensovibep, a multi-specific DARPin antiviral for COVID-19 with Novartis holding an option for further development.[pipeline] DARPin platforms also encompass Switch-DARPin T cell engagers with logic-gated activation for enhanced safety in solid tumors and the Radio-DARPin Therapy (RDT) platform for targeted alpha radionuclide delivery to solid tumors. Founded in 2004 and headquartered in Zurich-Schlieren, Switzerland, with additional offices in Cambridge and Concord, Massachusetts, USA, the company operates primarily in Europe and North America, targeting pharmaceutical partners and patients in oncology, hematology, and infectious diseases. Recent developments include the expansion of its strategic collaboration with Orano Med SAS in January 2025 to co-develop up to ten Radio-DARPin therapeutics, featuring lead candidates MP0712 and MP0726, with initial clinical data for MP0712 expected in the first half of 2026; presentation of new preclinical proof-of-concept data for logic-gated CD3 Switch-DARPins at SITC 2025 and initial human imaging data for MP0712 at TRP Summit Europe 2025; a June 2025 announcement of operational efficiencies involving a workforce reduction of approximately 24% (up to 40 positions) to extend cash runway into 2028 while prioritizing MP0533 and MP0712; and ongoing advancement of two clinical programs with positive topline data from ensovibep's Phase 2 COVID-19 trial in 2022.[pipeline]